Stühler, V.; Herrmann, L.; Rausch, S.; Stenzl, A.; Bedke, J.
Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab. Cancers 2022, 14, 2972.
https://doi.org/10.3390/cancers14122972
AMA Style
Stühler V, Herrmann L, Rausch S, Stenzl A, Bedke J.
Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab. Cancers. 2022; 14(12):2972.
https://doi.org/10.3390/cancers14122972
Chicago/Turabian Style
Stühler, Viktoria, Lisa Herrmann, Steffen Rausch, Arnulf Stenzl, and Jens Bedke.
2022. "Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab" Cancers 14, no. 12: 2972.
https://doi.org/10.3390/cancers14122972
APA Style
Stühler, V., Herrmann, L., Rausch, S., Stenzl, A., & Bedke, J.
(2022). Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab. Cancers, 14(12), 2972.
https://doi.org/10.3390/cancers14122972